2025-523850-15-00招募中4 期
Exogenous progesterone as ovulation trigger – a pilot study
Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2026年6月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of mature oocytes (MII) following progesterone-induced oocyte maturation.
研究概览
简要总结
To ascertain whether the exogenous administration of progesterone during the late follicular phase may trigger oocyte meiosis reactivation .
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Informed Consent Form dated and signed correctly prior to the performance of any study procedure.
- •Oocyte donors aged >17 and <34 years old in the moment of the recruitment.
- •Patients with regular menstrual cycles (between 25 to 35 days long).
- •Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).
- •Body Mass Index (BMI) between 18.5 and 28.
排除标准
- •Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.
- •Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).
- •Hypogonadotropic or hypergonadotropic hypogonadism.
- •Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.
- •Any condition contraindicating vaginal ultrasound and/or vaginal oocyte retrieval. These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator’s opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.
- •Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit
- •Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.
研究组 & 干预措施
Cyclogest 400 mg óvulos
Test
干预措施: Cyclogest 400 mg óvulos (Drug)
结局指标
主要结局
Number of mature oocytes (MII) following progesterone-induced oocyte maturation.
Number of mature oocytes (MII) following progesterone-induced oocyte maturation.
次要结局
- Endocrinological profile (E2, P4, LH and FSH) 12h after trigger
- Endocrinological profile (E2, P4, LH and FSH) on the morning of egg retrieval
研究者
Ana Raquel Neves
Scientific
Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda.
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
Exogenous Progesterone as Ovulation TriggerNCT07466199Instituto Valenciano de Infertilidade de Lisboa10
尚未招募
2/3 期
Comparison of Progesterone based stimulation with conventional protocol during the luteal phase of menstrual cycle in poor ovarian responders undergoing dual stimulation (DuoStim)CTRI/2024/03/064504All India Institute of Medical Sciences60
尚未招募
2 期
Triggering Ovulation in Normo-responders Using a Modified Dual Trigger Protocol or HCG TriggerInfertility (IVF Patients)NCT07569302Bedaya Hospital196
尚未招募
不适用
To compare the efficacy of platelet-rich plasma versus bone marrow-stem cell instillation in infertile women with decreased ovarian reserve undergoing IVF/ICSI treatmentCTRI/2025/03/083537AIIMS New Delhi39
招募中
2 期
Investigating Ovulation Inhibition for Use as a ContraceptiveNCT07365904Mylan Pharmaceuticals Inc60